Search
Now showing items 1-1 of 1
Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
(2016-10)
There are several options for switching people with multiple sclerosis (MS) who are at high risk of developing progressive multifocal leukoencephalopathy (PML) from natalizumab to alemtuzumab. However, some of these have ...